Search
Phosphatidylethanolamine Biosynthesis PE(20:0/18:4(6Z,9Z,12Z,15Z))
smpdb.ca/view/SMP0015414MetabolicPhosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...
Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 morePhosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:3(9Z,12Z,15Z))
smpdb.ca/view/SMP0015442MetabolicPhosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...
Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 moreAcylcarnitine (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine
smpdb.ca/view/SMP0124408Metabolic(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is an acylcarnitine. … once again form (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl-CoA and L-carnitine. (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl-CoA then enters into the mitochondrial
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalAs of 24 July 2018, however, the U.S. … Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersCOVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
go.drugbank.com/drugs/DB15845ExperimentalThe vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity. … As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’
Synonyms: AP-TP-V, COVID-19 AP TP VaccineBerberine
go.drugbank.com/drugs/DB04115ApprovedInvestigationalWithdrawnAn alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. … It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsCinnamaldehyde
go.drugbank.com/drugs/DB14184ApprovedIt occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to cinnamaldehyde may be identified with a clinical patch test. … Cinnamaldehyde is a naturally occurring flavonoid that gives the spice cinnamon its flavour and odour.
Categories: Compounds used in a research, industrial, or household settingAsparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigationalAsparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles;[L1452] thus, those who are allergic to [Asparaginase Escherichia coli] do … Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent.
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain. … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersTegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedTegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates